Which has better earnings & valuation, SGP or HYPR?

Spyglass Pharma has higher earnings, but lower revenue than Hyperfine. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spyglass Pharma N/A N/A N/A N/A N/A Hyperfine $11.40M 12.50 -$35.57M -$0.41 N/A

Is BBNX or HYPR more profitable?

Beta Bionics has a net margin of -60.27% compared to Hyperfine's net margin of -226.88%. Beta Bionics' return on equity of -23.00% beat Hyperfine's return on equity. Company Net Margins Return on Equity Return on Assets Beta Bionics -60.27% -23.00% -20.55% Hyperfine -226.88% -98.83% -67.09%

Does the media favor BBNX or HYPR?

In the previous week, Beta Bionics had 7 more articles in the media than Hyperfine. MarketBeat recorded 9 mentions for Beta Bionics and 2 mentions for Hyperfine. Hyperfine's average media sentiment score of 0.91 beat Beta Bionics' score of 0.07 indicating that Hyperfine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Hyperfine 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, NPCE or HYPR?

NeuroPace has higher revenue and earnings than Hyperfine. NeuroPace is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroPace $99.99M 5.33 -$21.47M -$0.65 N/A Hyperfine $11.40M 12.50 -$35.57M -$0.41 N/A

Is NPCE or HYPR more profitable?

NeuroPace has a net margin of -21.67% compared to Hyperfine's net margin of -226.88%. Hyperfine's return on equity of -98.83% beat NeuroPace's return on equity. Company Net Margins Return on Equity Return on Assets NeuroPace -21.67% -108.20% -18.50% Hyperfine -226.88% -98.83% -67.09%

Does the media favor NPCE or HYPR?

In the previous week, NeuroPace and NeuroPace both had 2 articles in the media. Hyperfine's average media sentiment score of 0.91 beat NeuroPace's score of 0.91 indicating that Hyperfine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroPace 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hyperfine 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer HYPR or TCMD?

In the previous week, Hyperfine and Hyperfine both had 2 articles in the media. Hyperfine's average media sentiment score of 0.91 beat Tactile Systems Technology's score of 0.62 indicating that Hyperfine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperfine 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tactile Systems Technology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, HYPR or MDXG?

MiMedx Group has higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hyperfine $11.40M 12.50 -$35.57M -$0.41 N/A MiMedx Group $389.42M 1.38 $48.58M $0.20 17.98

Is HYPR or MDXG more profitable?

MiMedx Group has a net margin of 7.88% compared to Hyperfine's net margin of -226.88%. MiMedx Group's return on equity of 21.03% beat Hyperfine's return on equity. Company Net Margins Return on Equity Return on Assets Hyperfine -226.88% -98.83% -67.09% MiMedx Group 7.88% 21.03% 15.92%

Does the media favor HYPR or MDXG?

In the previous week, Hyperfine and Hyperfine both had 2 articles in the media. MiMedx Group's average media sentiment score of 0.94 beat Hyperfine's score of 0.91 indicating that MiMedx Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperfine 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiMedx Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Hyperfine (HYPR) Competitors

$1.44 +0.04 (+2.50%)

As of 11:54 AM Eastern

Compare

HYPR vs. SGP, BBNX, NPCE, TCMD, and MDXG

Should you buy Hyperfine stock or one of its competitors? MarketBeat compares Hyperfine with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hyperfine include Spyglass Pharma (SGP), Beta Bionics (BBNX), NeuroPace (NPCE), Tactile Systems Technology (TCMD), and MiMedx Group (MDXG). These companies are all part of the "medical equipment" industry.

How does Hyperfine compare to Spyglass Pharma?

Spyglass Pharma (NASDAQ:SGP) and Hyperfine (NASDAQ:HYPR) are both small-cap medical equipment companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

In the previous week, Hyperfine had 1 more articles in the media than Spyglass Pharma. MarketBeat recorded 2 mentions for Hyperfine and 1 mentions for Spyglass Pharma. Spyglass Pharma's average media sentiment score of 1.87 beat Hyperfine's score of 0.91 indicating that Spyglass Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Spyglass Pharma	Very Positive
Hyperfine	Positive

Spyglass Pharma currently has a consensus price target of $45.00, suggesting a potential upside of 148.07%. Hyperfine has a consensus price target of $1.78, suggesting a potential upside of 24.27%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Spyglass Pharma is more favorable than Hyperfine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

15.0% of Hyperfine shares are held by institutional investors. 26.3% of Hyperfine shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Spyglass Pharma has a net margin of 0.00% compared to Hyperfine's net margin of -226.88%. Spyglass Pharma's return on equity of 0.00% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	N/A	N/A
Hyperfine	-226.88%	-98.83%	-67.09%

Spyglass Pharma has higher earnings, but lower revenue than Hyperfine.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	N/A	N/A	N/A
Hyperfine	$11.40M	12.50	-$35.57M	-$0.41	N/A

Summary

Spyglass Pharma beats Hyperfine on 7 of the 11 factors compared between the two stocks.

How does Hyperfine compare to Beta Bionics?

Beta Bionics (NASDAQ:BBNX) and Hyperfine (NASDAQ:HYPR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

Beta Bionics has a net margin of -60.27% compared to Hyperfine's net margin of -226.88%. Beta Bionics' return on equity of -23.00% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
Hyperfine	-226.88%	-98.83%	-67.09%

Beta Bionics presently has a consensus target price of $19.70, suggesting a potential upside of 43.59%. Hyperfine has a consensus target price of $1.78, suggesting a potential upside of 24.27%. Given Beta Bionics' stronger consensus rating and higher probable upside, research analysts clearly believe Beta Bionics is more favorable than Hyperfine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Beta Bionics had 7 more articles in the media than Hyperfine. MarketBeat recorded 9 mentions for Beta Bionics and 2 mentions for Hyperfine. Hyperfine's average media sentiment score of 0.91 beat Beta Bionics' score of 0.07 indicating that Hyperfine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Hyperfine	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.0% of Hyperfine shares are held by institutional investors. 5.3% of Beta Bionics shares are held by company insiders. Comparatively, 26.3% of Hyperfine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Beta Bionics has a beta of 3.4, indicating that its share price is 240% more volatile than the broader market. Comparatively, Hyperfine has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market.

Hyperfine has lower revenue, but higher earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$110.24M	5.55	-$73.20M	-$1.51	N/A
Hyperfine	$11.40M	12.50	-$35.57M	-$0.41	N/A

Summary

Beta Bionics beats Hyperfine on 10 of the 17 factors compared between the two stocks.

How does Hyperfine compare to NeuroPace?

NeuroPace (NASDAQ:NPCE) and Hyperfine (NASDAQ:HYPR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

78.8% of NeuroPace shares are held by institutional investors. Comparatively, 15.0% of Hyperfine shares are held by institutional investors. 20.5% of NeuroPace shares are held by insiders. Comparatively, 26.3% of Hyperfine shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

NeuroPace has a net margin of -21.67% compared to Hyperfine's net margin of -226.88%. Hyperfine's return on equity of -98.83% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-21.67%	-108.20%	-18.50%
Hyperfine	-226.88%	-98.83%	-67.09%

In the previous week, NeuroPace and NeuroPace both had 2 articles in the media. Hyperfine's average media sentiment score of 0.91 beat NeuroPace's score of 0.91 indicating that Hyperfine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroPace	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hyperfine	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NeuroPace has higher revenue and earnings than Hyperfine. NeuroPace is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$99.99M	5.33	-$21.47M	-$0.65	N/A
Hyperfine	$11.40M	12.50	-$35.57M	-$0.41	N/A

NeuroPace presently has a consensus price target of $18.83, suggesting a potential upside of 20.43%. Hyperfine has a consensus price target of $1.78, suggesting a potential upside of 24.27%. Given Hyperfine's higher probable upside, analysts plainly believe Hyperfine is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

NeuroPace has a beta of 1.88, suggesting that its stock price is 88% more volatile than the broader market. Comparatively, Hyperfine has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market.

Summary

NeuroPace beats Hyperfine on 9 of the 16 factors compared between the two stocks.

How does Hyperfine compare to Tactile Systems Technology?

Hyperfine (NASDAQ:HYPR) and Tactile Systems Technology (NASDAQ:TCMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

15.0% of Hyperfine shares are owned by institutional investors. Comparatively, 83.4% of Tactile Systems Technology shares are owned by institutional investors. 26.3% of Hyperfine shares are owned by company insiders. Comparatively, 2.1% of Tactile Systems Technology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Hyperfine and Hyperfine both had 2 articles in the media. Hyperfine's average media sentiment score of 0.91 beat Tactile Systems Technology's score of 0.62 indicating that Hyperfine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperfine	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tactile Systems Technology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tactile Systems Technology has a net margin of 5.91% compared to Hyperfine's net margin of -226.88%. Tactile Systems Technology's return on equity of 9.70% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-226.88%	-98.83%	-67.09%
Tactile Systems Technology	5.91%	9.70%	7.53%

Hyperfine currently has a consensus target price of $1.78, suggesting a potential upside of 24.27%. Tactile Systems Technology has a consensus target price of $38.60, suggesting a potential upside of 49.50%. Given Tactile Systems Technology's stronger consensus rating and higher probable upside, analysts clearly believe Tactile Systems Technology is more favorable than Hyperfine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Tactile Systems Technology	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86

Hyperfine has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market. Comparatively, Tactile Systems Technology has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

Tactile Systems Technology has higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40M	12.50	-$35.57M	-$0.41	N/A
Tactile Systems Technology	$343.52M	1.70	$19.09M	$0.88	29.34

Summary

Tactile Systems Technology beats Hyperfine on 12 of the 16 factors compared between the two stocks.

How does Hyperfine compare to MiMedx Group?

Hyperfine (NASDAQ:HYPR) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

MiMedx Group has a net margin of 7.88% compared to Hyperfine's net margin of -226.88%. MiMedx Group's return on equity of 21.03% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-226.88%	-98.83%	-67.09%
MiMedx Group	7.88%	21.03%	15.92%

Hyperfine has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market.

15.0% of Hyperfine shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 26.3% of Hyperfine shares are owned by company insiders. Comparatively, 2.5% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Hyperfine currently has a consensus price target of $1.78, indicating a potential upside of 24.27%. MiMedx Group has a consensus price target of $8.50, indicating a potential upside of 136.44%. Given MiMedx Group's stronger consensus rating and higher possible upside, analysts clearly believe MiMedx Group is more favorable than Hyperfine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

MiMedx Group has higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40M	12.50	-$35.57M	-$0.41	N/A
MiMedx Group	$389.42M	1.38	$48.58M	$0.20	17.98

In the previous week, Hyperfine and Hyperfine both had 2 articles in the media. MiMedx Group's average media sentiment score of 0.94 beat Hyperfine's score of 0.91 indicating that MiMedx Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperfine	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiMedx Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MiMedx Group beats Hyperfine on 13 of the 15 factors compared between the two stocks.

Get Hyperfine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HYPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HYPR vs. The Competition

Export

Metric	Hyperfine	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$142.45M	$7.04B	$6.49B	$11.72B
Dividend Yield	N/A	1.20%	2.67%	5.61%
P/E Ratio	-3.50	47.73	24.68	23.78
Price / Sales	12.50	45.23	476.92	85.99
Price / Cash	N/A	25.48	43.05	54.72
Price / Book	3.42	6.89	10.40	6.71
Net Income	-$35.57M	$159.22M	$3.56B	$337.26M
7 Day Performance	-4.33%	-5.21%	-2.69%	-2.08%
1 Month Performance	-18.00%	4.05%	-0.09%	0.74%
1 Year Performance	72.08%	-2.38%	20.93%	24.42%

Hyperfine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HYPR Hyperfine	3.3232 of 5 stars	$1.44 +2.5%	$1.78 +24.3%	+75.2%	$142.45M	$11.40M	N/A	190
SGP Spyglass Pharma	N/A	$18.38 +0.3%	$45.00 +144.9%	N/A	$612.49M	N/A	N/A	65	Gap Down
BBNX Beta Bionics	3.2753 of 5 stars	$12.76 -0.4%	$19.70 +54.4%	-28.8%	$570.39M	$110.24M	N/A	294	Gap Down
NPCE NeuroPace	3.4386 of 5 stars	$16.29 -1.3%	$18.83 +15.6%	+21.4%	$563.91M	$99.99M	N/A	170
TCMD Tactile Systems Technology	3.7802 of 5 stars	$24.42 +1.9%	$38.60 +58.0%	+150.9%	$555.10M	$343.52M	27.05	1,086	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HYPR) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hyperfine (HYPR) Competitors

HYPR vs. SGP, BBNX, NPCE, TCMD, and MDXG

How does Hyperfine compare to Spyglass Pharma?

Summary

How does Hyperfine compare to Beta Bionics?

Summary

How does Hyperfine compare to NeuroPace?

Summary

How does Hyperfine compare to Tactile Systems Technology?

Summary

How does Hyperfine compare to MiMedx Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYPR vs. The Competition

Hyperfine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hyperfine (HYPR) Competitors

HYPR vs. SGP, BBNX, NPCE, TCMD, and MDXG

How does Hyperfine compare to Spyglass Pharma?

Does the media refer more to SGP or HYPR?

Do analysts recommend SGP or HYPR?

Do insiders and institutionals have more ownership in SGP or HYPR?

Is SGP or HYPR more profitable?

Which has better earnings & valuation, SGP or HYPR?

Summary

How does Hyperfine compare to Beta Bionics?

Is BBNX or HYPR more profitable?

Do analysts recommend BBNX or HYPR?

Does the media favor BBNX or HYPR?

Do insiders & institutionals have more ownership in BBNX or HYPR?

Which has more volatility and risk, BBNX or HYPR?

Which has higher valuation & earnings, BBNX or HYPR?

Summary

How does Hyperfine compare to NeuroPace?

Do insiders and institutionals have more ownership in NPCE or HYPR?

Is NPCE or HYPR more profitable?

Does the media favor NPCE or HYPR?

Which has better valuation and earnings, NPCE or HYPR?

Do analysts rate NPCE or HYPR?

Which has more volatility and risk, NPCE or HYPR?

Summary

How does Hyperfine compare to Tactile Systems Technology?

Do institutionals and insiders hold more shares of HYPR or TCMD?

Does the media prefer HYPR or TCMD?

Is HYPR or TCMD more profitable?

Do analysts recommend HYPR or TCMD?

Which has more volatility & risk, HYPR or TCMD?

Which has better earnings and valuation, HYPR or TCMD?

Summary

How does Hyperfine compare to MiMedx Group?

Is HYPR or MDXG more profitable?

Which has more risk and volatility, HYPR or MDXG?

Do institutionals & insiders have more ownership in HYPR or MDXG?

Do analysts prefer HYPR or MDXG?

Which has better valuation and earnings, HYPR or MDXG?

Does the media favor HYPR or MDXG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYPR vs. The Competition

Hyperfine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools